{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-003326","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2025-05-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.580819+00:00","generated_at":"2026-05-21T00:53:35.597544+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aptose doses first patient at 120 mg tuspetinib in TUSCANY triplet trial after positive safety review","bullets":["CSRC cleared escalation to 120 mg TUS based on safety from 40 mg and 80 mg cohorts.","First patient dosed at 120 mg as part of TUS+VEN+AZA triplet frontline therapy for AML.","No prolonged myelosuppression or dose-limiting toxicities reported in first two cohorts.","Complete remissions and MRD negativity observed across diverse AML mutations.","Updated data to be presented at EHA 2025 congress (June 12-15) in Milan."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-003326","json":"https://secwatch.observer/filing/0001171843-25-003326.json","markdown":"https://secwatch.observer/filing/0001171843-25-003326.md","text":"https://secwatch.observer/filing/0001171843-25-003326.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184325003326/0001171843-25-003326-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184325003326/f8k_051925.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T00:53:35.597544+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}